Are there still opportunities in China and Asia for US biopharmas?

Seminar | October.19.2022 | 3pm - 5pm (Central Standard Time)

Orrick New York

China is the second largest pharmaceutical market in the world, growing to $205bn by 2026. With an increasing focus on innovation and early access, many US biopharmas have found that an anchor in China supports accelerated clinical development and creates incremental value via either through equity investments, direct entry or joint venture to access the Chinese and Asian markets, or milestones and anticipated royalties in the case of licensing. Do these opportunities still exist or has the window closed? What are the considerations in venturing into China and Asia? Join this Orrick and L.E.K. seminar to find out.

51 West 52nd Street New York

+1 212 506 5000

51 West 52nd Street
New York, NY 10019-6142
United States

T: +1 212 506 5000
F: +1 212 506 5151

Contacts

Stephen Thau Partner, Technology Companies Group, Life Sciences

New York; Silicon Valley

See my bio

D:+1 212 506 5076
E: [email protected]

Practice:

Technology & Innovation Sector
Technology Companies Group
Life Sciences
Mergers and Acquisitions
Governance aziendale
Capital Markets

vCard

See full bio

Stephen Thau Partner

New York; Silicon Valley

Stephen’s practice focuses on the representation of life science, medical device, health IT, and other technology companies in transactional matters, including public and private financings, licensing, collaborations and strategic alliances, and mergers and acquisitions. He also represents venture capital firms in public and private financing transactions.

Stephen is recognized as a Leading Life Sciences Lawyer by LMG Life Sciences in their 2021/2022 rankings and short-listed as Venture Capital Attorney of the Year. He has served as a member of the Board of Tech Council of Maryland, the leading technology and life science association in that state, and of BayBio, Northern California’s leading life sciences association. Stephen is a frequent speaker on venture capital financings and served on the faculty at the 2005 and 2007 Emerging Entrepreneurs workshops at Stanford University.

Prior to joining Orrick, Stephen was a partner at Morrison & Foerster, Venture Law Group and Heller Ehrman. He began his legal practice as a litigator, focusing on securities and intellectual property. ;He also served as a law clerk to the Hon. Vaughn R. Walker in the United States District Court in the Northern District of California. Stephen graduated Order of the Coif from Stanford Law School, where he was managing editor of the Stanford Law Review, and graduated magna cum laude from Harvard College in Biology.

David Schulman Partner, Capital Markets, Mergers and Acquisitions

Washington, D.C.

See my bio

D:+1 202 339 8654
E: [email protected]

Practice:

Life Sciences Sector
Technology & Innovation Sector
Capital Markets
Mergers and Acquisitions
Technology Companies Group
Technology Transactions

vCard

See full bio

David Schulman Partner

Washington, D.C.

He provides strategic guidance on transactions involving mergers, acquisitions, collaborations, strategic alliances, licenses, capital markets, royalty and revenue-sharing and other financings for pharmaceutical and biotechnology companies and financial sponsors.

David is highly ranked for his life sciences work by Chambers USA and Chambers Global, with clients recognizing him as “one of the best business and corporate lawyers in the life sciences sector” with “a deep knowledge of the industry, which he successfully combines with great legal skills.” He has also been recognized by The Legal 500 and is listed as a “Life Sciences Star” in LMG Life Sciences.

Prior to joining Orrick, David was a partner with Dechert LLP, based in its Washington, D.C., and London offices and was a co-head of their Life Sciences practice. He is currently a member of the Board of Overseers of the School of Arts and Sciences of the University of Pennsylvania.

Related Areas

Life Sciences